COMMUNIQUÉS West-GlobeNewswire

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
30/04/2026
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and [...]
UREVO Wins iF Design Award 2026 for AI-Powered Wireless Recovery Boots
30/04/2026
BERLIN, April 30, 2026 (GLOBE NEWSWIRE) -- Smart wellness innovator UREVO has been named an iF Design Award 2026 Winner for its AI-Powered Wireless Recovery Boots , reinforcing the brand's leadership in smart recovery [...]
EUROAPI_Contrat de liquidité
30/04/2026
Communiqué de presse Paris, 30 avril 2026 Programme de rachat d’actions Réduction de moyen au contrat de liquidité avec Kepler Cheuvreux Par contrat en date du 30 mai 2022, la société EUROAPI (ISIN: FR0014008VX5) a [...]
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
30/04/2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
EUROAPI_Liquidity Contract
30/04/2026
Press Release Paris 30 avril, 2026 Share buyback program Reduction in the Resources Allocated under the Liquidity Contract with Kepler Cheuvreux By agreement dated 30 May 2022, EUROAPI (ISIN: FR0014008VX5) entrusted [...]
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
30/04/2026
New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden [...]
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
30/04/2026
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered [...]
Nicox Provides Full Year 2025 Financial Results and Corporate Update
30/04/2026
Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024) NCX 470 U.S. New [...]
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
30/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming [...]
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04/2026
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, [...]
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
30/04/2026
OSE a abordé 2026 avec un plan stratégique clair à 3 ans, axé sur plusieurs catalyseurs à court terme pour lusvertikimab et Tedopi® 1 Trésorerie de 22,7 millions d’euros au 31 décembre 2025 et 17,0 millions d’euros au [...]
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
30/04/2026
Communiqué de presse Nicox annonce ses résultats financiers 2025 et fait un point sur son activité Chiffre d’affaires de 16,8 millions d’euros (7,9 millions d’euros en 2024) Perte nette significativement réduite à 2,4 [...]
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
30/04/2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Valneva annonce le succès d’une Offre Réservée d’un montant de 84 millions d’euros
30/04/2026
Lyon (France), le 30 avril 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce le succès d’une offre réservée d’un montant de 84 millions [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
Avalyn Announces Pricing of Upsized Initial Public Offering
30/04/2026
BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare [...]
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
30/04/2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ( [...]
Vaccinex Reports 2025 Annual Financial Results
30/04/2026
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and [...]
MIMEDX Announces First Quarter 2026 Operating & Financial Results
29/04/2026
Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE [...]

Pages